Overview

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

Status:
Not yet recruiting

Trial end date:
2023-04-28

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus tenofovir disoproxil fumarate-based antiretroviral regimens in HIV-infected individuals with virological suppression.

Phase:

Phase 4

Details

Lead Sponsor:

Shanghai Public Health Clinical Center

Collaborators:

Xixi Hospital of Hangzhou
Yunnan AIDS Care Center